$60M Catalyst Sale Gutted Company, Del. Investor Suit Says
IP Law 360
JUNE 16, 2022
A Catalyst Biosciences Inc. stockholder group has sued the company's directors for selling all its viable assets and keeping investors in the dark about plans for the $60 million in proceeds, claiming in a Delaware Chancery Court suit the board repeatedly breached its fiduciary duty.
40 
Let's personalize your content